Patents Assigned to Yissum Research Development Company of the Hebrew University
  • Patent number: 10723941
    Abstract: The present invention relates to a novel class of seeded nanoparticles and uses thereof.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: July 28, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Uri Banin, Itai Lieberman, Shany Neyshtadt, Lior Yedidya
  • Patent number: 10722599
    Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 28, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Rivka Cohen, Kirill Makedonski, Eylon Yavin, Andreas Ingemann Jensen, Keren Turjeman
  • Patent number: 10717664
    Abstract: The invention provides a process for the preparation of bismuth oxyhalide, comprising a precipitation of bismuth oxyhalide in an acidic aqueous medium in the presence of a reducing agent. Also provided are bismuth oxyhalide compounds doped with elemental bismuth Bi(0). The use of Bi(0) doped bismuth oxyhalide as photocatalysts in water purification is also described.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: July 21, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yoel Sasson, Hani Gnayem
  • Patent number: 10716825
    Abstract: Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: July 21, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Betty Schwartz, Einav Yehuda-Shnaidman, Lili Nimri
  • Patent number: 10716864
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 21, 2020
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer Mandelboim, Stipan Jonjic, Orit Berhani, Ariella Glasner
  • Publication number: 20200225579
    Abstract: Provided is a novel class of solid water-dispersible powders, including a plurality of water-insoluble photoinitiators in nanoparticle forms for use in water-based ink formulations.
    Type: Application
    Filed: March 20, 2020
    Publication date: July 16, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shlomo MAGDASSI, Liraz LARUSH, Ido COOPERSTEIN, Amol Ashok PAWAR
  • Patent number: 10695462
    Abstract: The invention disclosed herein generally provides implantable medical devices and implants that may be removed on-demand from a subject's body at any time after their implanting in the body, without necessitating invasive procedures.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: June 30, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Oded Shoseyov, Danny Porath, Ofra Benny, Yaron Bar-Lavie, Amos Ofer
  • Patent number: 10694968
    Abstract: Systems and method for classifying EEG signals of a human subject generated responsive to a series of images containing target images and non-target images. The EEG signals are in a spatio-temporal representation. The time points are classified independently, using a linear discriminant classifier, to compute spatio-temporal discriminating weights that are used to amplify the spatio-temporal representation, to create a spatially-weighted representation. Principal Component Analysis is used on a temporal domain for dimensionality reduction, separately for each spatial channel of the signals, to create a projection, which is applied to the spatially-weighted representation onto a first plurality of principal components, to create a temporally approximated spatially weighted representation.
    Type: Grant
    Filed: April 13, 2014
    Date of Patent: June 30, 2020
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Leon Y. Deouell, Amir B. Geva, Galit Fuhrmann Alpert, Ran El Manor, Shani Shalgi
  • Publication number: 20200181234
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David NAOR, Lora ESHKAR-SEBBAN, Keren-Or AMAR, Shmuel COHEN
  • Publication number: 20200171431
    Abstract: An air treatment unit may include an air inlet to receive a flow of input air for treatment and a reaction reservoir configured to hold an aqueous air treatment solution. The air treatment unit may also include an air dispersing element flow connected with the air inlet, wherein the air dispersing element is configured to convert at least a portion of the flow of input air into a plurality of microbubbles for introduction into the aqueous air treatment solution, such that an amount of one or more target gas species contained within the plurality of microbubbles is reduced through reaction with the aqueous air treatment solution. The unit may include an air outlet configured to output treated air from the reaction reservoir.
    Type: Application
    Filed: June 28, 2017
    Publication date: June 4, 2020
    Applicants: SALAMANDRA ZONE LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUALEM LTD.
    Inventors: Marat MAAYAN, Uri STOIN, Yoel SASSON, Doron Weinfeld
  • Patent number: 10670229
    Abstract: The present invention provides an optically active structure and the use thereof in a backlight unit. The optically active structure comprises a plurality of optically active particles configured to emit light of one or more predetermined wavelength range in response to pumping energy, and a plurality of light scattering elements. The plurality of light scattering elements comprises optically transparent void regions, such as void regions surrounding filler particles.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 2, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Uri Banin, Ehud Shaviv, Denis Glozman, Hagai Arbell
  • Patent number: 10669390
    Abstract: Provided is a unique class of foam materials characterized by regions of material unidirectionality. The foam materials are configured for a great variety of end-use applications as core materials or as materials in construction of multilayered structures. The novel and ingenious process for making the composite materials of the invention, permits modifying the foam materials to suite any specific end use.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 2, 2020
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Melodea Ltd.
    Inventors: Shaul Lapidot, Sigal Roth Shalev, Rikard Slattegard, Oded Shoseyov, Clarite Azerraf, Ido Braslavsky, Victor Yashunsky
  • Publication number: 20200165671
    Abstract: A method of determining the methylation status of at least one methylation site of a double-stranded DNA molecule is disclosed. The method comprises analyzing the methylation status of both the forward strand and the reverse strand of the DNA molecule.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yuval DOR, Ruth SHEMER, Benjamin GLASER, Judith MAGENHEIM
  • Patent number: 10662225
    Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.
    Type: Grant
    Filed: June 4, 2017
    Date of Patent: May 26, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Gabriel Nussbaum, Amnon Hoffman, Chaim Gilon
  • Publication number: 20200138977
    Abstract: Provided herein are pre-lyophilized compositions containing a nucleic acid, a cationic polymer, and a carbohydrate. Also provided are lyophilized compositions of matter and reconstituted compositions as well as methods of making using the same for treating tumors in patients.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 7, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Abraham HOCHBERG, Jennifer GALLULA
  • Publication number: 20200121581
    Abstract: Provided are methods, compositions and kits employing cellulose nanocrystals for hair-straightening treatment. Also provided are methods, compositions and kits employing a resilin, for hair-straightening treatment and/or for maintenance of straightened hair following a hair-straightening treatment.
    Type: Application
    Filed: April 4, 2018
    Publication date: April 23, 2020
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Smart Resilin Ltd.
    Inventors: Oded SHOSEYOV, Roni SHALEV, Sigal BARUCH-SHARON, Tal BEN SHALOM, Liron NUTTMAN-NESIAL
  • Patent number: 10624851
    Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 21, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventor: Saul Yedgar
  • Patent number: 10618807
    Abstract: The invention provides a process for the production of hydrogen, comprising catalytically decomposing a concentrated aqueous solution of potassium formate in a reaction vessel to form bicarbonate slurry and hydrogen, discharging the hydrogen from said reaction vessel, and treating a mixture comprising the bicarbonate slurry and the catalyst with an oxidizer, thereby regenerating the catalyst. Pd/C catalysts useful in the process are also described.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 14, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yoel Sasson, Harold Wiener, Ariel Givant
  • Publication number: 20200108037
    Abstract: The present invention is directed to a fatty acid amide of an amino acid, including a stereoisomer and a salt thereof for use in the treatment of a patient suffering from any type of addiction disorder, substance abuse disorder, including any condition and symptom associated therewith and including withdrawal syndrome and relapse addiction during and after a rehabilitation treatment of said patient.
    Type: Application
    Filed: May 22, 2018
    Publication date: April 9, 2020
    Applicants: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd., VIRGINIA COMMONWEALTH UNIVERSITY, UNIVERSITY OF GUELPH
    Inventors: Raphael MECHOULAM, Vincenzo DI MARZO, Fabiana PISCITELLI, Aron H. LICHTMAN, Imad M. DAMAJ, Linda PARKER, Rami YAKA
  • Patent number: 10611819
    Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 7, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: David Naor, Lora Eshkar-Sebban, Keren-Or Amar, Shmuel Cohen